On June 8, the state Senate debated House No. 2477/Senate No. 1705, which provides a pathway in New Jersey for access to lower-cost mimic therapies of expensive biologic drugs. The bill specifically details the communication requirements that must occur between a pharmacist, physician, and patient before the substitution of a biosimilar for the original biologic medicine can occur. Biosimilars are not the “new generic” of biologics because they cannot be exactly replicated, hence the need for clear access policies and close monitoring of patients.